Blood‑based biomarkers are reshaping #Alzheimers research. With this multiplexed assay, you get absolute quantification of five key CNS markers in one workflow:
Offered by Sapient, an Alamar Biosciences Certified Service Provider.
Request the assay: lnkd.in/dzK2_K_K
Proving Target Relevancy with FFPE Proteomics
This session shows how FFPE proteomics enables direct measurement of functional biology- revealing protein expression, pathway activation, immune activity, and resistance mechanisms in archived samples.
Full webinar: lnkd.in/g9Ec3taz
Sapient’s Mo Jain, MD PhD shares with The Analytical Scientist how multi‑omics platforms are using AI to translate massive molecular data into real clinical insight - accelerating biomarker discovery, trial design, and diagnostic innovation.
🔗 lnkd.in/gxMZreu3
New case study: Inflammatory profiling with NULISAseq™ + Sapient’s discovery #proteomics & #metabolomics uncovers previously unrecognized immune modulation in response to #GLP1 therapy.
Preview & download the full dataset: lnkd.in/gr_9wWkS
Metabolomics goes beyond genomics-capturing environmental, microbial & drug‑related biology in one readout. By measuring endogenous + exogenous #metabolites, it reveals how exposures shape disease.
See more use cases: lnkd.in/gd8Ahazf
De‑risk high‑value #Alzheimers programs with one blood‑based panel.
The NULISAqPCR™ AD 5‑plex Assay quantifies BD‑pTau217, Aβ42, GFAP, NfL & APOE4 – delivering a multidimensional readout of pathology, inflammation & #neurodegeneration.
Run by Sapient.
Learn more: lnkd.in/dzK2_K_K
Traditional biomarker panels miss the dynamic reality of human biology. Sapient was built to change that.
Our actionable omics capture proteins, metabolites, lipids & cytokines at scale – revealing functional biology that drives clearer insights and faster decisions.
Let's connect: lnkd.in/g7AkiQyJ
Now available: NULISAqPCR™ AD 5‑plex Assay.
Absolute quant of 5 key Alzheimer’s biomarkers-BD‑pTau217, NfL, Aβ42, GFAP, APOE4-from one ultra‑sensitive blood assay. Fast, high‑performance, and ideal for early detection + translational studies.
lnkd.in/dzK2_K_K
#ADassay #pTau #abeta #neuroinflammation
Metabolomics is complex – but foundation models can finally make it actionable. See how they unlock clinical trial insights on heterogeneity, risk, and design.
lnkd.in/gRZXs_wt
#metabolomics #foundationmodel #foundationmodeling
Why do patients with the same diagnosis respond differently to the same drug?
Because human biology is heterogeneous—and that complexity can’t be captured by genomics or single biomarkers alone.
Learn more here 👉 sapient.bio/resources/me...
#AI #Metabolomics
Upcoming Webinar | Proving Target Relevancy with FFPE Proteomics
📅 Feb 25 | 8:30am PT
Learn how next‑gen FFPE proteomics delivers direct, functional human evidence to validate targets and reduce late‑stage failures in precision oncology.
🔗 Register to attend the live event: lnkd.in/g9Ec3taz
“AI reveals structure in biological complexity that humans can’t define manually—and orthogonal validation is what makes those signals trustworthy.”
— Mo Jain, MD PhD, in The Analytical Scientist
#AI #Omics #Biomarkers 🔗https://lnkd.in/gYpwxUND
Did you know? Plasma metabolomics reveals system‑wide biology invisible to tissue‑specific markers.
By capturing circulating metabolites from multiple organs, it enables a holistic view of physiology, disease, and biomarker discovery.
🔗 sapient.bio/resources/me...
#Metabolomics
Unlock biomarker insights & responder profiles from #FFPE samples.
Sapient’s FFPE Multi-Omics Platform analyzes archived tissue to:
• Optimize stratification & dosing
• Identify target engagement
• Select responder subgroups
#ClinicalOncology study: lnkd.in/ghg4qHSa
#Metabolomics reveals phenotypic differences missed by genes or labs. Sapient uncovers:
• Therapy-response differences
• Exposure-modified genetic risk
• Biology behind phenotypic variation
• Metabolic signals before disease
#WhiteSheet: sapient.bio/resources/me...
Looking for a protein or target to modulate?
Explore Sapient’s interactive Protein Assay Menu — 12,000+ proteins by mass spectrometry:
lnkd.in/gv7rm2GT
Analyze proteins & PTMs across plasma, cells, and tissue (incl. FFPE).
Search by protein, gene, pathway, or phenotype.
Using large-scale #Metabolomics (1,600 samples), our #ML aging clock shows:
• Accelerated aging in chronic disease
• Severity-linked acceleration
• Reversal after therapy (e.g., transplant)
Case study: lnkd.in/grKqazn
AI in analytical science isn’t about hype-it’s about scale and context.
#Multiomics + AI moves us beyond single biomarkers toward true systems-level disease models.
Dr. Mo Jain discussed this with The Analytical Scientist: lnkd.in/gxMZreu3
White Paper: MS-based #FFPE proteomics marks a turning point in oncology R&D.
Direct quantification of tumor protein function -isoforms, PTMs, pathway activation, and resistance -without antibodies.
Learn more: lnkd.in/gj28XfWF
Get more from your #FFPE samples.
Turn archival tissue into a discovery engine.
Sapient’s FFPE Proteomics measures 10,000+ proteins across key oncogenes, drug targets & pathways to unlock new #biomarker insights.
➡️ lnkd.in/gZpnpwgU
Marker of the Month ⚛️: Creatinine.
A key kidney biomarker linked to #CKD, #T2D, cardiovascular & liver disease, but limited for early detection. With our DynamiQ™ Engine, we examined its disease ties and related metabolic markers.
eBook ⬇️ sapient.bio/resources/cr...
It’s not every day you celebrate a U.S. patent-let alone two! 🎉 We hosted a #PatentParty to mark a major milestone for Sapient, recognizing inventions behind our rLC-MS pipeline that advance the scale and accuracy of #biomarkerdiscovery.
More on our awarded patents: lnkd.in/dRHk3EPx
Thank you to our engaged audience and the gracious hosts of the #PACTSummit for the opportunity for Dr. Jonathan Usuka to present on omics-driven innovations in drug discovery and development.
#AnalyticalChemistry #PACTS #MultiOmics #Discovery
Outliers & missing data in #omics can complicate #biocomputational analysis — but also uncover hidden insights. Sapient’s Shreya Gaddam & Cameron Lamoreaux share strategies to handle missingness & outliers in large-scale #proteomics & #metabolomics data.
🔗 sapient.bio/resources/bi...
Our team had great time last week at #BiomarkersandPrecisionMedicineUS2025! Awesome talks on #multiomics & how our DynamiQ database + biorepository advance biomarker research. Thanks to all who stopped by Booth & our poster on immune modulation in weight loss! #BiomarkersandPrecisionMedicine
Innovation alert! Sapient has been granted two U.S. patents for our novel #massspectrometry signal processing + data normalization tech - powering more accurate, scalable #biomarker discovery.
Inventors: Dr. MoJain, Dr. Saumya Tiwari, and Dr.Jeramie Watrous!
Read here: sapient.bio/resources/ma...
Great first day at #BIOMUK2025!
Big thanks to everyone who joined Dr. Mo Jain’s talk & plenary panel - and to those who stopped by our booth to chat #multiomics.
We’ll be back tomorrow, come see us at Booth 52!
#BiomarkersandPrecisionMedicine #OGPremed #BiomarkersUK
We're excited to join Alamar's Precision Biomarker Summit this week in San Diego! 🧬
Sapient’s Tao Long will share insights on inflammatory profiles in obesity and how #NULISAseq reveals cytokine changes post-GLP-1 therapy.
Still time to register:
🔗 alamarbio.com/precision-bi...
Get your Omics Brief: a short talk on big shifts in drug development—this time exploring novel insights from a large-scale #metabolomics study.
What can thousands of metabolic profiles reveal about health, disease, and drug response?
Watch now: sapient.bio/resources/me...
In this Bioanalysis Zone interview, Sapient Co-Founders Jeramie Watrous and Tao Long explore how we use #AI and machine learning to transform complex data into actionable decisions.
sapient.bio/resources/om...
#biomarkers #multiomics #omicsanalytics #datatoinsight
